DBV Technologies (DBVT): Positive Sustained Efficacy for OIT Likely to Carry Over to Viaskin - Leerink

August 23, 2016 9:14 AM EDT
Get Alerts DBVT Hot Sheet
Price: $36.45 +2.24%

Rating Summary:
    6 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 28 | Down: 20 | New: 17
Trade DBVT Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Leerink Partners analyst, Joseph Schwartz reiterated his Outperform rating on DBV Technologies S.A (NASDAQ: DBVT) ahead of DBV's 3-year followup OLFUS-VIPES food challenge/sustained efficacy data in 4Q16/1Q17.

The analyst evaluated three published results for oral immunotherapy (OIT) in peanut allergy and concluded "Whereas early intervention with OIT engenders impressive desensitization to PA, we continue to believe DBV's epicutaneous immunotherapy (EPIT) has advantages of convenience, compliance and safety, and exclusivity that bode well for the product's commercial prospects and potential to expand the platform into other indications".

No change to the price target of $54.

For an analyst ratings summary and ratings history on DBV Technologies S.A click here. For more ratings news on DBV Technologies S.A click here.

Shares of DBV Technologies S.A closed at $34.56 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments

Add Your Comment